Navigation Links
Arena Pharmaceuticals' Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
Date:10/12/2009

SAN DIEGO, Oct. 12, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that lorcaserin will be featured in multiple presentations at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society in Washington, DC.

The line-up includes a late-breaking abstract oral presentation of results from BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management), a Phase 3 trial for which Arena reported positive, highly significant top-line results in September. Arena will also present new data analyses from lorcaserin's successful Phase 3 pivotal program in oral and poster sessions. In an independent clinical symposium, expert academic scientists and physicians will spotlight the 5HT-2C mechanism for weight management.

The positive results from our Phase 3 pivotal program highlight lorcaserin's potential to provide physicians with a treatment option that combines three important attributes - efficacy, safety and tolerability

"- critical to broad applicability in the majority of their patients to help manage weight and improve cardiometabolic health," stated William R. Shanahan, M.D., Arena's Vice President and Chief Medical Officer. "The breadth of presentations featuring lorcaserin at The Obesity Society's annual scientific meeting speaks to the strong interest physicians have in this drug candidate."

Obesity 2009: Presentation Schedule

    Saturday, October 24, 2009

        -- Pre-Conference Session: Pharmacotherapy Update
           Time: 1:00 - 3:45 p.m. Eastern Time (ET)
           Chairs: Ken Fujioka, M.D., Louis J. Aronne, M.D., and Richard
            Pratley, M.D.
           Presenter: Christen M. Anderson, M.D., Ph.D.

    Sunday, October 25, 2009

        -- Poster Session
           Time: on display 1:00 -
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 /PRNewswire-iReach/ -- This is a professional ... Heparin sodium (CAS 9041-08-1) & calcium (CAS 37270-89-6) ... of Heparin sodium (CAS 9041-08-1) & calcium (CAS ... The report then explores global and China,s top ... (CAS 37270-89-6) listing their product specification, capacity, production ...
(Date:7/30/2014)... ANTONIO , July 30, 2014   ... company focused on innovating lifesaving devices and methods ... $4.5 million in Series A financing, which was ... Proceeds from the deal will allow Bluegrass Vascular ... Access Catheter System, enhance manufacturing capabilities, and proceed ...
(Date:7/30/2014)... California , July 30, 2014 ... technology and CUDA programming expertise to big data, ... markets  eInfochips, a leading engineering R&D ... clients to develop NVIDIA GPU-powered solutions for ... high-performance computing (HPC), industrial , ...
Breaking Medicine Technology:Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2
... Reportlinker.com announces that a new market research ... Pharmaceuticals: Global Industry Guide ... Pharmaceuticals: Global Industry Guide is ... analysis covering the Pharmaceuticals industry. It includes ...
... 2012 Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE ... three lead drugs (Zertane™ completed two phase ... licensing distribution of these drugs and engaged in further ... interim review of the first 50% of patients enrolled ...
Cached Medicine Technology:Pharmaceuticals: Global Industry Guide 2Pharmaceuticals: Global Industry Guide 3Pharmaceuticals: Global Industry Guide 4Pharmaceuticals: Global Industry Guide 5Pharmaceuticals: Global Industry Guide 6Pharmaceuticals: Global Industry Guide 7Pharmaceuticals: Global Industry Guide 8Pharmaceuticals: Global Industry Guide 9Pharmaceuticals: Global Industry Guide 10Pharmaceuticals: Global Industry Guide 11Pharmaceuticals: Global Industry Guide 12Pharmaceuticals: Global Industry Guide 13Pharmaceuticals: Global Industry Guide 14Pharmaceuticals: Global Industry Guide 15Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule 2Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule 3Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule 4
(Date:7/30/2014)... Rancho Cucamonga, CA (PRWEB) July 30, 2014 ... career learning how to make millions. However, like most people, ... all. Determined to find a better way, Paul carefully ... lasting wealth and those who do not. Based on the ... learned to not only improve his life and health, but ...
(Date:7/30/2014)... sub-Saharan Africa is being revitalized and expanded through ... broadening curricula, upgrading Internet access and providing cutting-edge ... the first substantial publication by participants of the ... than 225 authors detailed progress being made at ... supplement being published today by the journal ...
(Date:7/30/2014)... July 30, 2014 Good Neighbor ... in an upcoming episode of Innovations with Ed ... Channel. Dates and show times TBA. , In ... Neighbor Community Services’ vision to redefine the traditional ... and dynamic services. Through passion, innovation, determination, excellence, ...
(Date:7/30/2014)... -- It can happen in an instant: A small child ... and gets critically injured when the furniture tips over. ... around their homes and imagine what could tip over, fall ... than it becoming a reality," Dr. Alex Rosenau, president of ... news release. Between 2009 and 2011, roughly 43,000 people ...
(Date:7/30/2014)... cancer as well as evolutionary changes in a living ... randomly throughout the genome. , However, recent studies have ... multiple mutations that arise simultaneously and in close proximity ... frequently found in regions where chromosomal rearrangements take place. ... Reports , may one day lead to new cancer ...
Breaking Medicine News(10 mins):Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:Tip-Over Furniture Can Kill Kids 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2
... macular degeneration, also called juvenile macular degeneration, is an ... This condition results from a defect in the ABCR ... that removes all-trans-retinaldehyde, a vision byproduct, from retinal rods ... epithelium (RPE), a layer of cells near the retina. ...
... inflammatory condition of the bladder wall. It typically affects ... men. Investigators are testing the bacteria Bacillus Calmette-Guerin(BCG), which ... treating interstitial cystitis, by inserting six installations into the ... study of BCG// also showed that 60 percent of ...
... a screening of the colon do not go through ... procedure that is currently available involves inserting a flexible ... requires anaesthesia and there's a remote chance that the ... patients now have an easier option with the discovery ...
... worldwide and its incidence is high in the Asian and ... foodstuffs. The cancer is also becoming prevalent in the United ... gene activity in liver tumors using the new 'gene chip' ... They found that there is a difference between// those tumors ...
... has shown that infants born during night time have ... to those born during day time. Previous studies have ... weekends and holidays have an increased risk of death ... experienced staff for better obstetric and neonatal care during ...
... Vitamin C has been believed, over the years, to be a ... proved to be true by researchers who have studied changes in ... their study of 12 healthy subjects who took one gram of ... immune system response in all of them during the period. Their ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: